Humana Raises $1 Billion Through 30-Year Subordinated Notes at 6.625%

Humana Inc. (NYSE: HUM) has successfully closed a $1 billion offering of subordinated notes due 2056, according to an SEC filing on March 9, 2026. The 30-year notes carry an initial fixed interest rate of 6.625% through September 2031, before resetting to a floating rate structure.

The Deal

The subordinated notes were priced at par (100% of face value) and will generate approximately $986 million in net proceeds after underwriting fees and expenses. The offering was led by a syndicate including Goldman Sachs, J.P. Morgan Securities, Mizuho Securities, Truist Securities, and Wells Fargo Securities.

The notes feature a unique structure with an initial fixed rate of 6.625% annually through September 15, 2031. After this date, the rate will reset every five years based on the five-year U.S. Treasury rate plus 2.891%, with a floor ensuring the rate never falls below 6.625%. Interest payments are scheduled semi-annually on March 15 and September 15, beginning September 2026.

A notable feature of these subordinated notes is Humana's option to defer interest payments for up to 10 consecutive years, provided no event of default has occurred. This flexibility provides the company with additional financial maneuvering room during potential market downturns or operational challenges.

Strategic Rationale

Humana has earmarked the proceeds for general corporate purposes, with a specific focus on repaying existing indebtedness, including borrowings under its commercial paper program. This refinancing strategy appears designed to extend the company's debt maturity profile while locking in long-term financing at current rates.

The subordinated nature of these notes places them junior to Humana's senior debt obligations in the capital structure. They are unsecured and will be effectively subordinate to any future secured indebtedness. Additionally, the notes are structurally subordinated to all indebtedness and liabilities at Humana's subsidiary level, meaning subsidiary creditors would have priority claims on subsidiary assets.

The 30-year maturity provides Humana with patient capital that doesn't require near-term refinancing, while the hybrid fixed-to-floating structure offers some protection against interest rate volatility. The 6.625% floor ensures predictable minimum interest costs even in a low-rate environment.

What to Watch

Several factors merit monitoring as this debt issuance settles into Humana's capital structure. The company's ability to service this additional debt will depend on operational performance in its core Medicare Advantage business, which has faced margin pressures from rising medical costs and regulatory changes.

The interest deferral option, while providing flexibility, could signal financial stress if exercised. Investors should watch for any signs that Humana might need to utilize this feature, as it would likely indicate operational headwinds or capital allocation challenges.

The reset mechanism beginning in 2031 introduces interest rate risk that could increase Humana's borrowing costs if Treasury rates rise significantly. However, the 6.625% floor provides downside protection, ensuring the company won't benefit from potential future rate decreases below this level.

From a credit perspective, the subordinated structure means these noteholders face higher risk than senior creditors. Rating agencies will likely scrutinize how this issuance affects Humana's overall leverage ratios and interest coverage metrics, particularly given the challenging operating environment for Medicare Advantage insurers.

The successful completion of this offering at par suggests market confidence in Humana's long-term creditworthiness, despite near-term industry headwinds. The company's decision to tap the debt markets now may reflect management's view that current rates remain attractive for long-term financing, even with the Federal Reserve's recent monetary policy stance.

*Source: SEC Form 8-K filed March 9, 2026*

— StockCliff Research